Abstract
Clinical Practice Points . Plasmablastic lymphoma (PBL) is a rare and highly aggressive variant of diffuse large B cell lymphoma with median survival of advanced stage patients varying between 6 and 15 months in previous reports. We report here a human immunodeficiency virus-infected patient surviving over 12 years following treatment for advanced PBL with EPOCH chemotherapy and intrathecal therapy. This case highlights the potential for improved survival in PBL with intensive chemotherapy. Further, literature review suggests promising prospects utilizing novel targeted therapies to increase the rate of prolonged responses.
Cite
CITATION STYLE
Rafei, H., El-Bahesh, E., Finianos, A., Liu, M.-L. L., & Schechter, G. P. (2017). Plasmablastic Lymphoma: Case Report of Prolonged Survival of an Advanced Human Immunodeficiency Patient and Literature Review. Case Reports in Hematology, 2017, 1–4. https://doi.org/10.1155/2017/9561013
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.